Against this backdrop, the present study assessed data from a longitudinal cohort of patients in a clinical setting who had T2D to determine the effectiveness of SGLT2i therapy compared with another commonly prescribed class of second-line GLAs, namely, dipeptidyl peptidase 4 inhibitors (DPP4is), for total cardiovascular conditions. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.